Enrollment Form Sarcoma (SARC)

Instructions: The Enrollment Form should be completed for each TCGA qualified case, upon qualification notice from the BCR. All

information provided on this form should include activity and known history from the date of initial diagnosis to the most recent date of contact with the patient ("Date of Initial Pathologic Diagnosis" and "Date of Last Contact" on this form).					
Questions regarding this form should be directed to the Tissue Source Site's primary Clinical Outreach Contact at the BCR.					
Please note the following definitions for the "Unknown" and "Not Evaluated" answer options on this form. Unknown: This answer option should only be selected if the TSS does not know this information after all efforts to obtain the data have been exhausted. If this answer option is selected for a question that is part of the TCGA required data set, the TSS must complete a discrepancy note providing a reason why the answer is unknown.					
obtaiı		e the test in question was never performed on the	own that the information being requested cannot be e patient or the TSS knows that the information		
Fissu	e Source Site (TSS):	TSS Identifier:	TSS Unique Patient Identifier:		
Comp	leted By (Interviewer Name	e in OpenClinica):	Completed Date:		
-	ral Information				
#	Data Element	Entry Alternatives	Working Instructions		
1	Is this a prospective tissue collection?	□ Yes □ No	Indicate whether the TSS providing tissue is contracted for prospective tissue collection. If the submitted tissue was collected for the specific purpose of TCGA, the tissue has been collected prospectively. <u>3088492</u>		
2	Is this a retrospective tissue collection?	□ Yes □ No	Indicate whether the TSS providing tissue is contracted for retrospective tissue collection. If the submitted tissue was collected prior to the date the TCGA contract was executed, the tissue has been collected retrospectively. <u>3088528</u>		
-	ient Information				
Dat	e of Birth		Provide the date the patient was born.		
3*	Date of Birth	Month Day Year	<u>2896950</u> (Month), <u>2896952</u> (Day), <u>2896954</u> (Year)		
4*	Gender	☐ Female ☐ Male	Provide the patient's gender using the defined categories. 2200604		
5	Race	 American Indian or Alaska Native Asian White Black or African American Native Hawaiian or other Pacific Islander: Not Evaluated Unknown 	 Provide the patient's race using the defined categories. <u>2192199</u> American Indian or Alaska Native: A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. Asian: A person having origins in any of the original peoples of the far East, Southeast Asia, or in the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. White: A person having origins in any of the original peoples of the far Europe, the Middle East, or North Africa. Black or African American: A person having origins in any of any of the black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African American." Native Hawaiian or other Pacific Islander: A person having origins in any of the original peoples of Negro" Landos. Not Evaluated: Not provided or available. Unknown: Could not be determined or unsure. 		
6	Ethnicity	 Not Hispanic or Latino Hispanic or Latino Not Evaluated Unknown 	 Provide the patient's ethnicity using the defined categories. 2192217 Not Hispanic or Latino: A person not meeting the definition of Hispanic or Latino. Hispanic or Latino: A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. Not Evaluated: Not provided or available. Unknown: Could not be determined or unsure. 		

Enrollment Form Sarcoma (SARC)

7	History of Other Malignancy	□ Yes □ No	Indicate whether the patient was, at any time in their life, diagnosed with a malignancy prior or synchonous to the diagnosis of the specimen submitted for TCGA. If the patient has had a prior or synchonous malignancy, an additional form (the "Other Malignancy Form") must be completed for each prior or synchronous malignancy. If the OMF was completed and submitted with the Initial Case Quality Control Form, the OMF does not need to be submitted a second time. <u>3382736</u> If this question cannot be answered because the answer is unknown, the case will be excluded from TCGA. If the patient has a history of multiple diagnoses of basal or squamous cell skin cancer, complete an OMF for the first diagnosis for each of these types.		
8	Neo-adjuvant (Pre- Operative) Therapy <i>for Tumor Submitted for TCGA</i>	□ Yes □ No	Indicate whether the patient received neo-adjuvant treatment (radiation, pharmaceutical, or both) prior to the collection of the tumor that yielded the sample submitted for TCGA. <u>3382737</u> Systemic therapy and certain localized therapies (those administered to the same site as the TCGA submitted tissue) given prior to the collection of the sample submitted for TCGA is exclusionary.		
9	Tumor Status (at time of last contact or death)	 Tumor free With tumor Unknown 	Indicate whether the patient was tumor/disease free at the date of last contact or death. 2759550		
10	Vital Status (at date of last contact)	□ Living □ Deceased	Indicate whether the patient was living or deceased at the date of last contact. $\underline{5}$		
11	Date of Last Contact	MonthDay Year	If the patient is living, provide the date of last contact with the patient (as reported by the patient, medical provider, family member, or caregiver). <u>2897020</u> (Month), <u>2897022</u> (Day), <u>2897024</u> (Year)		
12	Date of Death	Month Day Year	If the patient is deceased, provide the date of death. <u>2897026</u> (Month), <u>2897028</u> (Day), <u>2897030</u> (Year)		
13	Adjuvant (Post- Operative) Radiation Therapy	□ Yes □ No □ Unknown	Indicate whether the patient had adjuvant/ post- operative radiation therapy. <u>2005312</u> If the patient did have adjuvant radiation, the Radiation Supplemental Form should be completed.		
14	Adjuvant (Post- Operative) Pharmaceutical Therapy	☐ Yes ☐ No ☐ Unknown	Indicate whether the patient had adjuvant/ post- operative pharmaceutical therapy. <u>2785850</u> If the patient did have adjuvant pharmaceutical therapy, the Pharmaceutical Supplemental Form should be completed.		
Prim	ary Tumor Pathologic/ P	rognostic Information			
#	Data Element	Entry Alternatives	Working Instructions		
15	Histological Type	 Dedifferentiated liposarcoma Leiomyosarcoma (LMS)* Undifferentiated Pleomorphic Sarcoma (UPS), NOS Pleomorphic 'MFH' / Undifferentiated pleomorphic sarcoma Giant cell 'MFH' / Undifferentiated pleomorphic sarcoma with giant cells Inflammatory 'MFH' / Undifferentiated pleomorphic sarcoma with prominent inflammation Malignant Peripheral Nerve Sheath Tumors (MPNST) Desmoid Tumor Myxofibrosarcoma Synovial Sarcoma - Monophasic Synovial Sarcoma - Poorly differentiated 	Using the patient's pathology/laboratory report, select the histology and/or subtype of the tumor submitted for TCGA. <u>3081934</u> If the histological type is Leiomyosarcoma, please complete the three additional questions below. For all other histological subtypes these three questions can be skipped.		

Enrollment Form Sarcoma (SARC)

#	Data Element	Entry Alternatives	Working Instructions
# 16	Leiomyosarcoma: Histological Subtype	 Well-differentiated leiomyosarcoma (resembling leiomyoma) Conventional leiomyosarcoma Poorly differentiated/ pleomorphic/ epithelioid leiomyosarcoma 	If the histological subtype is Leiomyosarcoma, using the patient's pathology/laboratory report, select the histological subtype of the tumor submitted for TCGA. 2831122
17	Leiomyosarcoma: Uterine Involvement	☐ Yes ☐ No ☐ Unknown	If the histological subtype is Leiomyosarcoma, using the patient's pathology/ laboratory report, indicate whether there was uterine involvement. 2775554
18	Leiomyosarcoma: Major Vessel Involvement	 No Unknown Yes - NOS Yes - Jugular/carotid Yes - Subclavicular Yes - Superior vena cava/chest Yes - Inferior vena cava Yes - Brachial vein/ axillary vein Yes - Brachial vein/ 	If the histological subtype is Leiomyosarcoma, using the patient's pathology/ laboratory report, indicate whether there was major vessel involvement. If the patient did have major vessel involvement, indicate where it was located. 3243330
19	Synovial Sarcoma: SS18-SSX Fusion Status	 Positive - SS18-SSX1 Positive - SS18-SSX2 Positive - Subtype Negative Unknown 	Using the patient's pathology/cytogenetics/molecular diagnostics laboratory report, indicate whether evidence of an SS18-SSX fusion was reported and the testing method. <u>3733516</u>
20	Synovial Sarcoma: SS18-SSX Testing Method	 RT-PCR FISH for SS18 split Both Unknown 	Using the patient's pathology/cytogenetics/molecular diagnostics laboratory report, indicate the testing method for SS18-SSX. <u>3733517</u>
21	MPNST: Does the patient have neurofibrobromatosis?	□ NF1 □ NF2 □ No □ Unknown	Using the patient's medical records, indicate whether the patient had neurofibrobromatosis. <u>3733521</u>
22	MPNST: If the patient has neurofibrobromatosis, is it familial or sporadic?	 □ Familial □ Sporadic □ Unknown 	If the patient had neurofibromatosis, indicate if it was known to be familial or sporadic. <u>3733535</u>
23	MPNST: Pre-exisiting plexiform neurofibroma at site of MPNST?	☐ Yes ☐ No ☐ Unknown	Using the patient's medical records, indicate whether the patient had pre-exisiting plexiform neurobibroma at site of MPNST. <u>3733551</u>
24	MPNST: Was NF1 Genetic Testing Performed?	 Yes, mutations identified Yes, mutations were NOT identified No Unknown 	Using the patient's medical records, indicate whether NF1 genetic testing was performed. <u>3733556</u>
25	MPNST: If NF1 genetic testing was performed and mutations were identified, please identify the specific mutations.		If NF1 genetic testing was performed, provide any specific mutations that were identified. <u>3733558</u>
26	Tumor Depth	 Superficial Deep Unknown 	Using the patient's pathology/laboratory report, indicate the depth of the tumor. <u>3808610</u>
27	Primary Site of Disease	Head & NeckRetroperitoneum/HeadUpper abdominalNeckRetroperitoneumOther, specifyIntraabdominalChestKidneyLung/pleuraLiverMediastinumColonChest wallGastric	Using the patient's pathology/laboratory report, select the anatomic site of disease of the tumor submitted for TCGA. 2735776 If the histological type is Leiomyosarcoma and the primary site of disease is skin, this case is excluded.

Enrollment Form Sarcoma (SARC)

#	Data Element	Entry Alt	ernatives	Working Instructions	
		 Diaphragm Breast Other, specify Superficial Trunk Abdominal wall Buttock Flank Back Other, specify Upper Extremity Shoulder/axilla Upper arm/elbow Forearm Hand/wrist Other, specify Lower Extremity Thigh/knee Groin Lower leg/calf Foot/ankle Other, specify 	 Duodenum Small Intestines Pancreas Other, specify Lower abdominal/ Pelvic Bladder Prostate Rectum Spermatic Cord Scrotum/testis Other, specify Gynecological Uterus Ovary Cervix Fallopian tube Other, specify 		
28	Other Primary Site of Disease			If the primary site of disease on the pathology/laboratory report is not available or does not specifically match the provided sites above, describe the site(s) of disease. <u>2584114</u>	
29	Date of Initial Pathologic Diagnosis	Month Day	Year	Provide the date the patient was initially pathologically diagnosed with the malignancy submitted for TCGA. <u>2896956</u> (Month), <u>2896958</u> (Day), <u>2896960</u> (Year)	
30	Margin Status	 □ Positive (+) ≤ 1mm □ Negative (-) □ Unknown 		Provide the margin status after the patient's first surgical procedure. <u>3114007</u>	
31	Residual Tumor	□ RX □ R0	□ R1 □ R2	Using the patient's pathology/laboratory report, select the residual tumor status after the surgical resection. 2608702	
32	Necrosis of Total Tumor	 0% (no necrosis or no <10% ("focal necrosis" Moderate Necrosis (Extensive Necrosis (Complete or if listed (therapy effect) 	") ≥10, <50%) >50%)	Using the patient's pathology/laboratory report, select the necrosis of the total tumor. If a specific percentage of necrosis is available, answer the following question. 3300612	
33	Percent Necrosis of Total Tumor			Indicate the percent necrosis of the entire tumor as recorded either at the time of resection or during subsequent analysis. <u>2841237</u>	
34	Mitotic Count		10 high power fields)	Using the patient's pathology/laboratory report, provide the patient's mitotic count. This should be the number mitoses per 10 high powered fields (10 HPF \cong 2.2 mm ²). <u>3227319</u>	
35	Is Disease Multifocal?	☐ Yes ☐ No ☐ Unknown		Using the patient's pathology/laboratory report, indicate whether the disease was multifocal. <u>64356</u>	
36	Number of Discontiguous Lesions			Using the patient's pathology/laboratory report, provide the number of discontiguous lesions. <u>3162604</u>	
	Tumor Size: Include both well-differentiated and de-differentiated components. (If there were multiple lesions, complete this question for each lesion)				
		Radiologic Length	(cm)	Provide the length for this tumor, when available as reported on the CT scan or MRI, immediately preceding the surgical resection. <u>3528021</u>	
37	Radiologic Tumor Size	Radiologic Width	(cm)	Provide the width for this tumor, when available as reported on the CT scan or MRI, immediately preceding the surgical resection. <u>3528033</u>	
		Radiologic Depth	(cm)	Provide the depth for this tumor, when available as reported on the CT scan or MRI, immediately preceding the surgical resection. 3528032	

Enrollment Form Sarcoma (SARC)

V4.08 102414

#	Data Element	Entry Al	ternatives	Working Instructions
		Pathologic Length	(cm)	Provide the length for this tumor, when available as examined pathologically at the time of the surgical resection. 3528034
38	Pathologic Tumor Size	Pathologic Width	(cm)	Provide the width for this tumor, when available as examined pathologically at the time of the surgical resection. 3528041
		Pathologic Depth	(cm)	Provide the depth for this tumor, when available as examined pathologically at the time of the surgical resection. <u>3528040</u>
39	Radiologic Tumor Burden			Provide the sum of the maximum diameter of the primary tumors as reported on the CT scan or MRI immediately preceding surgical resection. This should include both well- differentiated and de-differentiated components. <u>3162636</u>
40	Pathologic Tumor Burden			Provide the sum of the maximum diameter of the primary tumors as examined pathologically at the time of the surgical resection. This should include both well-differentiated and de- differentiated components. <u>3162641</u>
41	Locoregional Recurrence	☐ Yes □ No	Unknown	Indicate whether the patient had a local recurrence associated with the tumor submitted for TCGA. <u>62652</u>
42	Metastasis (Radiologic Evidence)	☐ Yes ☐ No ☐ Unknown		Indicate whether the patient was diagnosed with a distant metastasis with radiologic evidence. <u>65384</u>
43	Location of Metastasis	□ Lung □ Bone □ Liver	☐ Unknown☐ Other, specify	If the patient had a metastatic tumor associated with the diagnosis of the tumor submitted for TCGA, provide the site of the metastasis. If there was more than one metastatic site, select all that apply. <u>3124499</u>
44	Other Location of Metastasis			If the site of the metastasis was not included in the list provided, please provide the site. $\underline{3124503}$
45	Contiguous Organ/ Structure Resection	 Adrenal Bladder Colon Inferior vena cava (IVC) 	 ☐ Kidney ☐ Liver ☐ Small Bowel ☐ Spleen ☐ Unknown ☐ Other, specify 	If the patient had a contiguous organ/ structure removed, indicate the location of the contiguous organ. <u>3162811</u>
46	Other Contiguous Organ/ Structure Resection			If the site of the contiguous organ/ structure was not included in the list provided, describe the organ. <u>3162812</u>
47	Contiguous Organ Invaded	☐ Yes □ No □ Unknown		Indicate whether the tumor invaded a contiguous organ. <u>3162817</u>
48	Dedifferentiated Liposarcoma: Prior Diagnosis of Well Differentiated Liposarcoma	□ Yes □ No □ Unknown		Indicate whether the patient had a prior diagnosis of well differentiated liposarcoma. <u>3162681</u> Only answer this question if the histological subtype for tumor submitted to TCGA is dedifferentiated liposarcoma. All other subtypes can skip the remaining questions.
Date of <u>Primary Diagnosis</u> of Well Differentiated Liposarcoma				
49	Date Primary Diagnosis of Well Differentiated Liposarcoma			If the patient had a prior diagnosis of well differentiated liposarcoma, provide the date of this diagnosis. <u>3162688 (Month)</u> , <u>3162689</u> (Day), <u>3162690</u> (Year)
Date	e of <u>Resection</u> of Well Differ	Month Day	Year	
Dau		entatea Esposal coma		If the patient had a prior diagnosis of well differentiated
50	Date Resection of Well Differentiated Liposarcoma	Manth D		liposarcoma, provide the date the tumor was removed. <u>3162705 (Month)</u> , <u>3162706</u> (Day), <u>3162707</u> (Year)
		Month Day	Year	
New	ew Tumor Event Information Complete this section if the patient had a new tumor event. If the patient did not have a new tumor event (or if the TSS does not know) indicate this in the question below, and the remainder of this section can be skipped.			

Note: The New Tumor Event section on OpenClinica can be completed multiple times, if the patient had multiple New Tumor Events.

Enrollment Form Sarcoma (SARC)

#	Data Element	Entry Alto	ernatives	Working Instructions
51	New Tumor Event After Initial Treatment?	☐ Yes ☐ No ☐ Unknown		Indicate whether the patient had a new tumor event (e.g. metastatic, recurrent, or new primary tumor) after their initial treatment. 3121376
52	Type of New Tumor Event	 Locoregional/Recurrence Distant Metastasis New Primary Tumor 		Indicate whether the patient's new tumor event was a locoregional recurrence, a distant metastasis or a new primary tumor. 3119721
53	Site of New Tumor Event	□ Lung □ Bone □ Liver	 □ Brain □ Unknown □ Other, specify 	Indicate the site of this new tumor event. 3108271
54	Other Site of New Tumor Event			If the patient had a new tumor event and the site of this tumor was not included in the provided list, describe the site. <u>3128033</u>
Date	of New Tumor Event after l	nitial Treatment		
<u>55</u>	Date of New Tumor Event	Month Day	<u></u> Year	If the patient had a new tumor event, provide the date of diagnosis for this new tumor event. <u>3104044</u> (Month), <u>3104042</u> (Day), <u>3104046</u> (Year)
<u>56</u>	Additional Surgery for New Tumor Event	☐ Yes ☐ No ☐ Unknown		Using the patient's medical records, indicate whether the patient had surgery for the new tumor event in question. <u>3427611</u>
Date	e of Additional Surgery for I		applicable)	
<u>57</u>	Date of Additional Surgery for New Tumor Event	Month Day	<u>Year</u>	If the patient had surgery for the new tumor event, provide the date this surgery was performed. <u>3427612</u> (Month), <u>3427613</u> (Day), <u>3427614</u> (Year)
<u>58</u>	Residual Tumor after Surgery for New Tumor Event	RX R0	□ R1 □ R2	Using the patient's pathology/laboratory report, select the residual tumor status after the surgical resection for the new tumor event. 3104061
<u>59</u>	Is Disease Multifocal?	□ Yes □ No □ Unknown		Using the patient's pathology/laboratory report, indicate whether the new tumor was multifocal. <u>3524937</u>
<u>60</u>	Number of Discontiguous Lesions			Using the patient's pathology/laboratory report, provide the number of discontiguous lesions for the new tumor. <u>3526717</u>
		Radiologic Length	(cm)	Provide the length for the new tumor, when available as reported on the CT scan or MRI, immediately preceding the surgical resection of the new tumor. <u>3527990</u>
<u>61</u>	Radiologic Size of New Tumor	Radiologic Width	(cm)	Provide the width for the new tumor, when available as reported on the CT scan or MRI, immediately preceding the surgical resection of the new tumor. <u>3527997</u>
		Radiologic Depth	(cm)	Provide the depth for the new tumor, when available as reported on the CT scan or MRI, immediately preceding the surgical resection of the new tumor. <u>3527996</u>
		Pathologic Length	(cm)	Provide the length for the new tumor, when available as examined pathologically at the time of the surgical resection of the new tumor. <u>3528003</u>
<u>62</u>	Pathologic Size of New Tumor	Pathologic Width	(cm)	Provide the width for the new tumor, when available as examined pathologically at the time of the surgical resection of the new tumor. <u>3528020</u>
		Pathologic Depth	(cm)	Provide the depth for the new tumor, when available as examined pathologically at the time of the surgical resection of the new tumor. <u>3528004</u>
<u>63</u>	Radiologic Burden of New Tumor			Provide the sum of the maximum diameter of the new tumors as reported on the CT scan or MRI immediately preceding surgical resection. This should include both well-differentiated and de-differentiated components. <u>3526720</u>

Enrollment Form Sarcoma (SARC)

#	Data Element	Entry Alternatives	Working Instructions
<u>64</u>	Pathologic Burden of New Tumor		Provide the sum of the maximum diameter of the new tumors as examined pathologically at the time of the surgical resection. This should include both well-differentiated and de- differentiated components. <u>3526721</u>
<u>65</u>	Is the New Tumor Well- Differentiated or De- Differentiated? (Check all that apply)	Well-DifferentiatedDe-Differentiated	Indicate whether the newly diagnosed tumor is well- differentiated or de-differentiated. <u>3194001</u>
<u>66</u>	Additional treatment for New Tumor Event: <i>Radiation Therapy</i>	□ Yes □ No □ Unknown	Indicate whether the patient received radiation treatment for this new tumor event. <u>3427615</u>
<u>67</u>	Additional treatment for New Tumor Event: Pharmaceutical Therapy	☐ Yes □ No □ Unknown	Indicate whether the patient received pharmaceutical treatment for this new tumor event. <u>3427616</u>
		estions are only to be answered if the Tissue Source Si data if you have received permission from the NCI to provide ti	ite is unable to provide the dates requested on this form. me intervals as a substitute for requested dates on this form.
i	Has this TSS received permission from the NCI to provide time intervals as a substitute for requested dates on this form?	□ Yes □ No	Please Note : The time intervals must be recorded in place of dates where designated throughout this form if you have selected "yes" in the box. Provided time intervals must begin with the date of initial pathologic diagnosis (i.e., biopsy or resection).
ii	Number of Days from Date of Initial Pathological Diagnosis to Date of Birth	days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date of birth. <u>3008233</u>
iii	Number of Days from Date of Initial Pathological Diagnosis to Date of Last Contact	days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date of last contact. <u>3008273</u>
iv	Number of Days from Date of Initial Pathological Diagnosis to Date of Death	days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date of death <u>3165475</u>
v	Age at Initial Diagnosis	days	Provide the age of the patient in years, at the time the patient was initially pathologically diagnosed with the tumor submitted for TCGA. 2006657
vi	Number of Days from Date of Initial Pathologic Diagnosis to Diagnosis of Well Differentiated Liposarcoma	days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date the patient was diagnosed with primary well differentiated liposarcoma. <u>3523205</u>
vii	Number of Days from Date of Initial Pathologic Diagnosis to Resection of Well Differentiated Liposarcoma	days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date of the resection of well differentiated liposarcoma. <u>3523210</u>
viii	Number of Days from Date of Initial Pathological Diagnosis to Date of New Tumor Event After Initial Treatment	days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of new tumor event after initial treatment. <u>3392464</u>

Enrollment Form Sarcoma (SARC)

V4.08 102414

ix	Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event	days	Provide the number of days from date of initial pathologic diagnosis to date of additional surgery for new tumor event 3008335

Principal Investigator Signature

Date

I acknowledge that the above information provided by my institution is true and correct and has been quality controlled.